Search

for
Search:

GlossarySonidegib (Odomzo)

inhibits Hedgehog pathway to treat advanced basal cell carcinoma

Sonidegib, also known as Odomzo, is a medication used to treat advanced basal cell carcinoma, a type of skin cancer. It works by inhibiting the Hedgehog signaling pathway, which is crucial for the growth and survival of cancer cells.

Related Terms

Learn

0 / 0 results

— no results

Research

4 / 4 results

research From Basal Cell Carcinoma Morphogenesis to Alopecia Induced by Hedgehog Inhibitors: Connecting the Dots

17 citations, June 2017 in “British Journal of Dermatology”

The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.

research A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma

25 citations, January 2021 in “Journal of drugs in dermatology”

Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.

Smoothened Receptor Inhibitor Vismodegib for the Treatment of Basal Cell Carcinoma: A Retrospective Analysis of Efficacy and Side Effects

research Smoothened Receptor Inhibitor Vismodegib for the Treatment of Basal Cell Carcinoma: A Retrospective Analysis of Efficacy and Side Effects

8 citations, May 2019 in “Journal of dermatological treatment”

Vismodegib is effective for basal cell carcinoma but has severe side effects.

research A Systematic Summary of Survival and Death Signaling During the Life of Hair Follicle Stem Cells

31 citations, August 2021 in “Stem Cell Research & Therapy”

The conclusion is that understanding how hair follicle stem cells live or die is important for maintaining healthy tissue and repairing injuries, and could help treat hair loss, but there are still challenges to overcome.

Community Join

0 / 0 results

— no results